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Abstract
Islet allotransplantation in the United States (US) is facing an imminent demise. Despite nearly
three decades of progress in the field, an archaic regulatory framework has stymied US clinical
practice. Current regulations do not reflect the state-of-the-art in clinical or technical practices.
In the US, islets are considered biologic drugs and “more than minimally manipulated”

human cell and tissue products (HCT/Ps). Across the world, human islets are appropriately defined
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as “minimally manipulated tissue” which has led to islet transplantation becoming a standard-ofcare procedure for patients with type 1 diabetes mellitus and problematic hypoglycemia. As a
result of the outdated US regulations, only eleven patients underwent allo-ITx in the US between
2011-2016 and all in the setting of a clinical trial.
Herein, we describe the current regulations pertaining to islet transplantation in the

United States. We explore the progress which has been made in the field and demonstrate why
the regulatory framework must be updated to both, better reflect our current clinical practice
and to deal with upcoming challenges. We propose specific updates to current regulations which
are required for the renaissance of ethical, safe, effective, and affordable allo-ITx in the United
States.

Introduction
Human islets are considered a minimally manipulated tissue for transplantation and regulated as
solid organ transplantation in many countries.1 This approach to regulations allowed allogeneic
islet transplantation (allo-ITx) to become a standard of care procedure (Table S1B). In contrast, in
the United States (US), human islets have been considered a biologic drug and despite the
completion of federally funded clinical trials, have remained under development for the last 20
years.1,2 A heavy regulatory burden along with financial, logistical, and legal hurdles have limited
the development of this therapy.2 As a result, a private company is currently the only entity in the

process of obtaining exclusive rights for the marketization of human islets. This trend toward
commercialization of human organs and the rising cost will negatively affect the field of
transplantation.
Herein, we report on the current status of allo-ITx and provide an overview of current

regulations vis-à-vis the advances in scientific knowledge and clinical practice in the past 27 years.
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We call for an urgent update of the outdated regulatory framework, which would permit islet
allografts to be regulated as a minimally manipulated tissue and remain a public resource for
transplantation with clinical oversight under the same regulatory framework as organ
transplantation.
Regulations related to allo-ITx in the US
The principles of regulation of Somatic Cellular Therapy by the Food and Drug Administration

(FDA) remain unchanged since their inception in 1993 (Table 1).3,4 Human cell and tissue products
(HCT/Ps) are recognized as “more than minimally manipulated”, if their biological characteristics are
significantly altered before or following clinical application.4 These HCT/Ps follow the same
development steps as any new drug under Section 351 of the Public Health Service (PHS) Act. This
requires pre-clinical and clinical testing, pre-marketing approval based on the biologics license
application (BLA), and implementation of all necessary standards during production, distribution,
and marketing.4 The regulatory burden is progressive, with costs increasing dramatically as phases of
development are completed.3
However, some HCT/Ps do not require such extensive regulatory oversight and are exempt

from BLA approval; they are regulated solely under Section 361 of the PHS Act.4 For example,

autologous islets are exempt from BLA since their biological characteristics are not substantially
altered during processing. Islet isolation includes mechanical separation and enzymatic digestion of
the pancreas to isolate islets from acinar tissue and is routinely performed in FDA certified
laboratories known as a Good Manufacturing Practice (GMP) facilities (Table 1;6).
In contrast, the FDA regulates the islet allograft as a new biologic drug and has mandated a

BLA for the past 27 years, despite the fact that the entire processing protocol, technology,
materials, equipment, and facilities are exactly the same for the isolation of both allogeneic and
autologous islets.5
Why are allogenic and autologous islets regulated differently despite being processed identically?
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1) Autologous islets are infused into the patient immediately following isolation.6 In contrast,
allogeneic islets are preserved in culture media prior to infusion and could potentially bring
upon biological alterations. This assumption has led the FDA to determine that allogeneic
islets do not meet the “minimal manipulation” standard met by autologous islets and thus to
require BLA approval for allo-islets.5

Admittedly, islet allografts were originally cultured for several days to limit acinar tissue in the
islet preparation before transplantation. However, this practice was replaced by routine
mechanical islet purification 20 years ago.7 For example, “fresh” (i.e. uncultured) islet infusions

were utilized in a multicenter phase 1/2 clinical trial in the US (2001-2005).8 In the subsequent

clinical trials, islets were maintained for up to 72 hours prior to infusion for logistical reasons (to
prepare the patient for the procedure).9–12 Since islets, similarly to whole organs, but in contrast

to stem cells, cannot be stored frozen, they were placed in an incubator with the goal of
preservation only (i.e. to maintain their biological structure and function).9,10 The medium used
for islet preservation has no growth factors and contains only supplements that are allowed
during “minimal manipulation” according to FDA guidelines (Table 1;3).9 Extensive validation

studies performed during the Clinical Islet Transplantation Consortium (CITC) trial confirmed
that incubation did not alter the relevant biological characteristics of human islets. The integrity

and function of the islets were preserved and maintained at optimum quality until infusion.9,10
Therefore, short-term incubation of islet allografts meets the criteria for HCT/P preservation
and islets should NOT be considered as “more than minimally manipulated”.
2) Islet allograft has a systemic effect, and as such, in order to be exempt from BLA, should
meet one of the following 21 Code of Federal Regulations (CFR) 1271(a) 4 (ii) criteria:
(a) for autologous use,
(b) for allogeneic use in a first-degree or second-degree blood relative, or
(c) for reproductive use.
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Autologous islets meet criterion 4(ii) (a) for BLA exemption. Islet allografts indeed have NOT
met any of the 4(ii) criteria, and therefore, have not been exempt from BLA. However, criterion
4(ii) (b) for HCT/P with systemic effect, allowing allogeneic use in first or second degree

relatives to be exempt from BLA, is an antiquated immunological perspective which no longer

reflects the current state of scientific knowledge and clinical practice; degree of relatedness is
actually insufficient to ensure the safety and efficacy of HCT/Ps.
In 1993, clinical outcomes were indeed better among first and second-degree relatives

than among unrelated individuals. Currently, we no longer rely on biological relationships but
instead use appropriate immunological matching. In fact, the risk of immunologic sensitization

among first-degree relatives might be higher in the case of exposure of the mother to human
leukocyte antigens (HLA)s from the child or father during pregnancy and delivery. Thus,
allogeneic transplants’ safety and efficacy are ensured by immunological
matching/compatibility, based on detection of pre-existing donor-specific HLA alloantibodies in
the recipient’s blood in addition to the donor and recipient HLA tissue types. In the current era,
the safety and efficacy of related and unrelated but appropriately matched donor/recipient
pairs are comparable.13,14 Additionally, rules of immunological matching might differ among

various HCT/P therapies and treated diseases. For example, in type 1 diabetes mellitus (T1DM)
we avoid HLA matching due to an increased risk of recurrent autoimmunity.15 Regardless,
criterion 4(ii)b is intended to improve and ensure immunological safety and should be updated

in accordance to the advanced immunological matching algorithms that are currently in clinical
practice.

Allo-ITx experience in the US
Transformative progress in allo-ITx was achieved in 2000, when a series of seven patients

with T1DM remained insulin-free for one year post-procedure.7 At that time, the FDA confirmed that
islet allografts needed to be regulated and tested as a new drug. Federally funded clinical trials were
conducted over a span of the next 15 years and involved several US academic centers with a total
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expenditure of over $100M (Table S1;A). The results achieved by this collaborative endeavor have
played a crucial role in the establishment of allo-ITx worldwide, but oddly, not in the US.
Despite proven safety and efficacy, the adoption of allo-ITx has been deterred by US

regulatory constraints.2 The manufacturer of the islet product has an obligation to perform
additional validations and submit documentation for a BLA to the FDA for approval owing to the
extensive regulations imposed on new biologics.3,4 The cost of preparing a BLA submission is $5-6
million, alongside other significant costs and responsibilities related to liability, operations, and
additional regulations associated with the post-licensing processes.2 Unfortunately, even with FDA

permission to utilize common clinical results for an individual center submission, none of the
academic centers participating in the trials have been able to submit their own BLA due to these
logistical, financial and legal challenges.2,4
Consequences of the current regulations on the status of allo-ITx in the US
1) Near extinction of islet transplantation in the US
To date, no BLA has been approved; therefore, no islets have been transplanted outside of
clinical trials nor reimbursed by medical insurance in the US. Additionally, limited research
funding and the high procedural costs (>$138,000) are inherent constraints.16 In the US, only
11 new patients received an allo-ITx in the past four years in contrast to 179 islet transplants
performed between 1999-2005 (Figure 1).

2) No access for Americans with severe hypoglycemia to a lifesaving procedure
Among the 1.2 million Americans with T1DM, approximately 375,000 suffer from impaired
hypoglycemic awareness and 66% suffer from recurrent severe hypoglycemic episodes
(SHE).17 Most importantly, nearly 70,000 T1DM patients fail to improve despite structured
education and advanced technologies for hypoglycemia avoidance.18,19 Quality of life for
these patients and their families is severely compromised by sudden and unexpected
episodes of loss of consciousness, frequently leading to disability and fatal accidents.
Additionally, anxiety and depression are related to an increased risk of death secondary
to unrecognized hypoglycemia.19 Despite significant improvements in insulin pumps and
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continuous glucose monitoring sensors, hypoglycemic episodes have remained a
significant hurdle for patients with T1DM in the US leading to an estimated 40,000
annual visits to emergency departments.20,21 Overall mortality rates remain at 4% for
medically optimized patients in contrast to no deaths in those who underwent islet
transplantation.22,23 Pancreas transplantation remains an approved therapeutic option
effectively treating diabetes in this subset of patients. However, it requires major
surgery with a 10-20% risk of operative complications.24 Allo-ITx is a minimally-invasive
alternative especially for nonsurgical candidates with lower morbidity and mortality,
improved glycemic control and prevention of SHE, even when subsequent procedures
are required to maintain long-term insulin independence (Table S1).24,25 Allo-ITx should
be avoided in patients with chronic kidney disease to limit immunologic sensitization
prior to kidney transplantation, unless applied as simultaneous islet-kidney or islet
following kidney transplantation. Islet and pancreas transplantation require continuous
administration of immunosuppression. Other modern cellular therapies (encapsulated
pluripotent stem cell derived islet transplantation and xenotransplantation) have been
tested clinically but are still under development.

3) Islet allografts are exempt from BLA and transplanted in many developed countries, except
in the US
Islet processing technology initially developed in the US has been freely adopted worldwide.
Results from US clinical trials prompted regulatory agencies in other countries to recognize,
in contrast to the FDA, that the biological characteristics of islet allografts do NOT change
during processing and preservation/incubation prior to transplantation (Table 1;8) 1.
Therefore, islets have been classified as minimally manipulated HCT/Ps and exempt from BLA
in these countries (Figure 2). Islets are processed according to cGMP (current GMP)
regulations adopted from the FDA (Table 1;6). Clinical safety and efficacy outcomes have
remained excellent, while allo-ITx is performed in accredited transplant centers worldwide
(Table S1;C).22,26,27 Additionally, under the same conditions (i.e. cGMP without BLA), islets
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were transplanted during clinical trials in the US. In the most experienced programs, five-year
insulin independence rates are ~ 50% and more importantly, allo-ITx confers complete
protection from severe hypoglycemic episodes in ≥ 90% of patients (Table S1;D).26,28
Notably, countries outside of the US ensure access to human islets by limiting
commercialization and providing reimbursement by national health systems (Figure 2, Table
S1;B).1

In 2019 the American Society of Transplantation's Board of Directors and the Council of the
American Society of Transplant Surgeons called upon the FDA to address these needed changes in
islet allograft regulation. A comprehensive proposal including the data and rationale presented in
this article was submitted and presented to the FDA during the meeting in February 2020. However,
the FDA has not pursued any updates (Table 1;3).
Recommendations for an updated regulatory framework for islet allografts
Our proposal calls for a regulatory update in line with current scientific knowledge and standards of
clinical practice. We propose the implementation of combined oversight of islet transplantation with
the FDA regulating islet processing and Organ Procurement and Transplantation Network (OPTN)/
United Network for Organ Sharing (UNOS) overseeing clinical islet transplantation. The US
Department of Health and Human Services should promote this structure via agency oversight which
aligns with its mission to protect the public’s health and improve the health system.
1. Update current FDA regulations

We urge the FDA to update current regulations and allow islet allografts to be included in the
products listed in 21 CFR 1271.10(a)(4)(ii) that are regulated solely by Section 361 of the PHS Act,
allowing exemption from BLA, as is the case for islet autografts (Table 1;3).
Specifically, we recommend that the FDA:
A) Confirm that islet allograft meets minimal manipulation criteria based upon current
evidence from the US and ongoing worldwide clinical practices. Specifically, it should be noted
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that short-term incubation prior to islet allograft infusion does not substantially change the
biological characteristics of human islets.
B) Update criterion 4 (ii) (b), which currently states: “use for in first and second degree
relatives” to reflect current scientific understanding and practice. We propose revising the
phrase to state, “use in immunologically compatible donors and recipients” instead, as this more
accurately represents the current clinical standards of matching in organ and cell/tissue

transplantation, and improves safety and efficacy of HCT/P.
Moreover, the original authors of regulation 21 CFR Part 1271 foresaw the evolving nature of

the science of allo-ITx. In 1993, they wrote, “… as these novel therapeutic applications are explored
and knowledge about the risk and benefit accumulates, the FDA regulatory approach may well be
modified.”3 Consequently, we should re-assess and update allo-ITx regulations in accordance with
currently available science and clinical practice.
2. Introduce additional clinical oversight by OPTN/UNOS

In accordance with current FDA regulations, islets manufactured after BLA approval will fall under
the purview of drug regulation and can be administered without the need for any clinical outcome
oversight nor program accreditation from OPTN/UNOS. However, allo-ITx is similar to solid organ
transplantation and involves risks of immunosuppression, transmission of infections, and allosensitization. Thus, the care of these patients demands highly specialized, multidisciplinary approach
with properly structured medical and social support to achieve optimal clinical benefit. Lack of
clinical oversight, as would be provided by OPTN/UNOS, may lead to inadequacy of monitoring and
data tracking, and inferior outcomes. Furthermore, islet allograft anatomy, physiology, and
preservation techniques more closely resemble those of other human organs rather than any drug
or single cell biologics (Figure S1). Similar to other solid organ transplantation, post-procedural
outcomes following allo-ITx undoubtedly are better suited to assess the quality of donor tissue after
processing than any pre-transplant in vitro testing. Therefore, adherence to BLA standards for alloITx is conceptually flawed and should be replaced by close post-transplant outcome monitoring by
the OPTN/UNOS (Figure 2)(Table 1;9-12).28,29
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What will happen if we do NOT update the islet allograft regulation?
Since not-for-profit organizations have not been able to offset the burden, liability, and costs related
to BLA, only a corporate entity with appropriate resources can adhere to the current islet regulatory
framework. However, this scenario is unlikely to expand access to safe, affordable, and equitable
allo-ITx.
Islets are recognized by FDA as a biological drug for a rare disease (<200,000 patients with

T1DM and complicated hypoglycemia in the US) and qualify for Orphan Drug Designation
(ODD)(Table 1;7) which portends seven years of marketing exclusivity. Currently, only one entity, a
for-profit company, CellTrans, has received an ODD and submitted a BLA to the FDA in May 2020
with decision regarding approval due by April 2021 (personal communication; Dr. José Oberholzer,
Aug. 20, 2020). This creates an imminent ethical and legal dilemma in which a private company may
have exclusive rights to benefit from altruistic human organ donation. This possibility would
undermine the public goods concept of organ donation and may undermine the public’s trust in the
national organ donation system. Prevention of islet commercialization was one of the reasons cited
by the European Union in its decision to exclude islets from regulation as a biologic.1,28
Assurances of a waiver of exclusivity are insufficient, when considered with the market forces

generated by the enormous costs of a BLA, pharmaceutical grade production, and quality control,
which may triple current allo-ITx costs (up to $500,000 per transplant). Undoubtedly, a for-profit
market approach, especially without competition, can lead to rising prices. Consequently, the price
charged for the procedure will become unnecessarily overinflated, less affordable, essentially cost
prohibitive, and perhaps not reimbursed by payors based on an unfavorable cost-to-benefit ratio. If
private payors provide coverage, rather than the Center for Medical Services (CMS), this may
disproportionately disadvantage patients of low social-economic status. Even if CellTrans waives the
exclusivity rights, the extreme cost and burden related to BLA submission (100,000 pages of
documents, reports of 1.5 million data points) [personal communication; Dr. José Oberholzer, Aug.
20, 2020)]) and the cost and burden of operations afterwards in a relatively small market will
effectively discourage any potential competitors.
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Furthermore, uncontrolled distribution of islet products without any clinical surveillance

system in place may lead to poor clinical outcomes and hinder advances in clinical management.
Typical post-marketing FDA oversight based only on voluntarily reporting of adverse events to the
manufacturer is insufficient to control allo-ITx clinical safety and effectiveness.
What will happen once requested updated regulations for allo-ITx are put in place?
We anticipate several positive impacts of the proposed regulatory update (Table S2): 1) The human
pancreas and isolated islets will be protected from commercialization and remain a public resource
as in other countries. The center transplanting a patient will be ultimately responsible for clinical
outcomes and may choose to process the islets in its own cGMP facility or to outsource that service.
Competition among institutions would lead to direct quality improvements and price regulations. 2)
BLA related regulatory barriers will be removed, allowing allo-ITx to become a standard-of-care
procedure based on the recommendation by experts and professional societies. 3) Payors can be
approached for reimbursement. 4) Not-for-profit academic centers will be able to process the islets,
providing safe and cost-effective treatments. 5) Clinical oversight from OPTN/UNOS will ensure
optimal clinical outcomes. 6) The number of islet isolation centers will increase, and competition will
drive improvement in quality, cost-effectiveness, and patient access to the procedure. 7) As the cost
of the procedure declines, it will be more affordable and comparable to pancreas transplantation
even if two or three allo-ITxs are required. 8) Significant allo-ITx clinical activity will reinvigorate
interest in research. Each of these listed factors would further facilitate scientific understanding and
clinical progress. Advances in islet (a micro-organ) transplantation would stimulate progress in
regenerative medicine, cellular therapies, and organ bioengineering. Ultimately, this would benefit
our patients and strengthen diabetic care in our health system.
Additional safety and quality considerations
If regulations are updated, 1) high standards of allo-ITx will be reinforced by OPTN/UNOS program
accreditation and transparent surveillance of outcomes (Table 1;9-12). Similar to pancreas
transplant programs, outcome measures including waitlist mortality rates, transplantation rates, and
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1-year and 3-year patient and graft survival rates, will be monitored by the OPTN and publicly
reported by the Scientific Registry of Transplant Recipients (SRTR) on a bi-annual basis. The OPTN
Pancreas and Islet Transplantation Committee remain vigilant and regularly update polices and
bylaws to ensure safety and efficacy. Islet graft
failure criteria can be adopted from the experts’ consensus.30 2) Islets would fall under 21 CFR Part

1271 Section 361 PHS, and still require mandatory processing in cGMP facilities emphasized by the
FDA and as a prerequisite for program OPTN accreditation.
The FDA established high standards of cGMP for drug manufacturing, specifically to ensure drug
sterility, potency, and traceability (Table 1;6). Adherence to cGMP also assures the identity, strength,
quality, and purity of drug products by requiring that manufacturers control operations adequately.
Each islet processing GMP facility is subject to FDA registration, certification, and unannounced
visits/inspection. Therefore, following FDA cGMP regulations during the islet processing, as we
propose, will satisfy islet product safety and efficacy requirements. The BLA requirement is designed
for any new drug entering an open market without any outcome control measures; however, under
the proposed regulatory framework, the BLA requirement will become obsolete as human islets will
be under oversight by the dual surveillance systems of OPTN/UNOS and FDA cGMP manufacturing
control. Additionally, ample scientific evidence from over 2,000 procedures worldwide, including
clinical trials in the US collected by CITR, sufficiently justifies the addition of allo-ITx to the list of
other HCT/Ps exempt from BLA without any compromise in safety or outcomes.10,28,29 The OPTN

could set expected outcomes initially at the level of a phase 3 CITC trial with the same product
release criteria and clinical indications. Standards can be modified based upon observed advances in
clinical outcomes. Programs will need to comply with requirements to obtain and maintain
accreditation for allo-ITx and will need to prove their capability and show appropriate track records.
Improved results in a number of centers can be expected as more experience is gained.
Underperforming centers will need to improve under supervision of the OPTN Membership and
Professional Standards Committee, and if unsuccessful may lose OPTN accreditation and contracts
for reimbursement.
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Summary
Urgent regulatory updates that incorporate current clinical standards and research findings

are indispensable for the re-introduction of ethical, safe, effective and affordable allo-ITx in the
United States. The US Department of Health and Human Services should promote updated
regulations and a new oversight framework to improve and protect the public’s health and
strengthen the US health system.
DisclosureThe authors of this manuscript have no conflicts of interest to disclose as described by the American
Journal of Transplantation.
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Figure 1. Catastrophic decline of allo-ITx procedures in the US
NIH- National Institute of Health; JDRF- Juvenile Diabetes Research Foundation;
BLA- Biological License Application
Figure 2. Status of islet transplantation in the US and worldwide proposed regulatory update


Islet allograft regulated as a drug by FDA since 1993.



15 years of clinical research supported by over $100M of US taxpayer funding did not benefit






US patients, although benefits were enjoyed by other patients worldwide; islet allograft
processing were recognized by regulatory agencies worldwide as minimal manipulation
based on US trial results and islets were exempt from BLA and regulated as a tissue/organ
transplantation instead of a drug or biologics.
Islet transplantation is still not a standard-of-care procedure in the US, despite already being
an established procedure in other countries.
Islet allograft regulation as a drug by FDA resulted in a series of negative consequences.
Situation will worsen after BLA is granted to a for-profit entity (negative consequences
marked with yellow color).
Proposed solution- regulatory update based on the current scientific data from US clinical
trials and CITR, which would result in islet exemption from BLA and islets regulation as organ
transplantation with clinical oversight by OPTN/UNOS and islet processing according to cGMP
FDA regulations (dashed arrow).

EMA- European Medicine Agency (like FDA in US), ATMP – Advanced Therapy Medicinal Product,
BLA- biological license application, CITR- Collaborative Islet Transplantation Registry, OPTN- Organ
Procurement and Transplantation Network, UNOS- United Network for Organ Sharing, cGMPcurrent good manufacture practice, FDA- Food and Drug Administration
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BLA- Biological License Application

Figure 2. Status of islet transplantation in the US and worldwide proposed regulatory update


Islet allograft regulated as a drug by FDA since 1993.
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15 years of clinical research supported by over $100M of US taxpayer funding did not benefit
US patients, although benefits were enjoyed by other patients worldwide; islet allograft
processing were recognized by regulatory agencies worldwide as minimal manipulation
based on US trial results and islets were exempt from BLA and regulated as a tissue/organ
transplantation instead of a drug or biologics.
Islet transplantation is still not a standard-of-care procedure in the US, despite already being
an established procedure in other countries.
Islet allograft regulation as a drug by FDA resulted in a series of negative consequences.
Situation will worsen after BLA is granted to a for-profit entity (negative consequences
marked with yellow color).
Proposed solution- regulatory update based on the current scientific data from US clinical
trials and CITR, which would result in islet exemption from BLA and islets regulation as organ
transplantation with clinical oversight by OPTN/UNOS and islet processing according to cGMP
FDA regulations (dashed arrow).
EMA- European Medicine Agency (like FDA in US), ATMP – Advanced Therapy Medicinal
Product, BLA- biological license application, CITR- Collaborative Islet Transplantation Registry,
OPTN- Organ Procurement and Transplantation Network, UNOS- United Network for Organ
Sharing, cGMP- current good manufacture practice, FDA- Food and Drug Administration
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